Last reviewed · How we verify
Aspirin plus clopidogrel
At a glance
| Generic name | Aspirin plus clopidogrel |
|---|---|
| Also known as | Cardioaspirina, Plavix, Aspirin+clopidogrel |
| Sponsor | Azienda Ospedaliera di Perugia |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- The Effect and Safety of Combined Anti-platelet Treatment in Acute Ischemic Stroke Due to Large Artery Atherosclerosis (PHASE4)
- Short-Term Anticoagulation Versus Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure (PHASE4)
- Randomized Clinical Trial of Endovascular Recanalization for Symptomatic Non-Acute Intracranial Artery Occlusion（REPAIR） (NA)
- Clopidogrel vs. Aspirin for Cardiovascular Risk Reduction in Patients With S. Aureus Bacteremia (PHASE4)
- Precision Reperfusion Therapy for Disabling Minor Stroke With Large Vessel Occlusion Beyond Time Window (PHASE3)
- SIMPLAAFY Clinical Trial (NA)
- STrategies for Antithrombotic tReatment Following Transcatheter Edge-to-Edge Repair in Patients Without an Indication for Oral Anticoagulant (PHASE4)
- Tailoring Bleeding Reduction Approaches in Patients Undergoing PCI (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Aspirin plus clopidogrel CI brief — competitive landscape report
- Aspirin plus clopidogrel updates RSS · CI watch RSS
- Azienda Ospedaliera di Perugia portfolio CI